Skip to main content
TipRanks
Go Ultimate75% OFF

Jazz Pharmaceuticals (JAZZ) AI Stock Analysis

1,945 Followers
JAZZ

Jazz Pharmaceuticals

(NASDAQ:JAZZ)

Select Model
Rating:67Neutral
Price Target:$249.00â–²(3.44% Upside)
Action:downgraded
Date:11/04/26

The score is driven primarily by strong cash flow generation and very high gross margins, supported by a strongly positive earnings update with raised 2026 guidance and encouraging Ziihera launch indicators. These positives are tempered by elevated leverage and earnings volatility, while the technical picture is mixed and valuation is stretched with a high P/E and no dividend support.

Positive Factors
Strong cash generationRobust operating and free cash flow gives Jazz internal funding capacity for product launches, pipeline development, acquisitions and debt management. Because cash generation has generally tracked reported earnings, it also supports the quality and durability of the company’s operating model.
Negative Factors
Elevated leverageElevated debt reduces financial flexibility even though leverage has improved from 2022 levels. Interest obligations and refinancing needs can constrain investment choices, particularly if product growth slows or Jazz must fund additional acquisitions and development programs.

Jazz Pharmaceuticals Key Performance Indicators (KPIs)

Neroscience Revenue BreakdownHighlights revenue generated from neuroscience products, indicating the company's strength and focus in treating neurological disorders, and potential growth in this specialized market.

$0.00$200.00M$400.00M$600.00M$800.00MMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26Sep 26
Chart Insights

Jazz’s neuroscience mix has structurally shifted: legacy Xyrem has collapsed while Xywav has scaled to become the primary growth engine, effectively replacing lost oxybate revenue and underpinning management’s raised guidance and double‑digit Xywav outlook for 2026. Epidiolex is a steady, expanding second pillar with lifecycle initiatives that can sustain upside. Sativex and Sunosi are now immaterial. Watch risks: potential oxybate generics and rising royalty-driven margin pressure plus higher SG&A/R&D could temper profit leverage even as top-line momentum accelerates.

Data provided by:The Fly

Jazz Pharmaceuticals (JAZZ) vs. SPDR S&P 500 ETF (SPY)

-10%0%10%20%30%40%50%JAZZ+36.97%SPY+11.73%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$15.39B
Dividend Yield
―
Average Volume (3M)
878.88K
Price to Earnings (P/E)
67.3
Beta (1Y)
0.53
Revenue Growth
13.48%
EPS Growth
―
Country
US
Employees
2,890
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Jazz Pharmaceuticals Business Overview & Revenue Model

Company Description

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopat...

How the Company Makes Money

Jazz Pharmaceuticals makes money primarily by selling prescription medicines, generating revenue when its products are ordered and reimbursed through pharmaceutical distribution channels. The company’s key revenue stream is net product sales (gross s...

Jazz Pharmaceuticals Earnings Call Summary

Earnings Call Date:Nov 02, 2026(Q3-2026)|% Change Since:12.25%|Next Earnings Date:Mar 02, 2027
Earnings Call SentimentPositive

The call was strongly positive. Jazz reported record revenue, raised full-year revenue and gross-margin guidance, delivered strong growth across oncology and Xywav, and described an encouraging early launch for Ziihera supported by favorable clinical data and market access. The company also highlighted substantial cash generation, pipeline progress and the Actio acquisition. Offsetting factors included lower adjusted gross margin, a reported non-GAAP loss driven by the Actio acquired IPR&D charge, a measured near-term Modeyso revenue pace, and future competitive pressure for Zepzelca. The positive operating and strategic developments significantly outweighed the stated challenges.

Positive Updates

Record Quarterly Revenue and Raised Guidance
Third-quarter revenue reached a record $1.24 billion, up 10% year-over-year. The company raised and narrowed 2026 total revenue guidance to $4.775 billion to $4.85 billion, with the midpoint representing nearly 13% growth over 2025.

Negative Updates

Adjusted Gross Margin Declined Year-over-Year
Non-GAAP adjusted gross margin declined by 110 basis points year-over-year, primarily because of royalties on higher Modeyso and Zepzelca sales and technology transfers for manufacturing several products.

Company Guidance

For 2026, Jazz raised and narrowed total revenue guidance to a range of $4.775 billion to $4.85 billion, representing nearly 13% growth over 2025 at the midpoint; rare sleep revenue is now expected to be $2.125 billion to $2.175 billion, led by Xywav growth of low double digits to low teens, while non-GAAP gross margin guidance increased by 50 basis points to a range of 90.5% to 91.5%, non-GAAP effective tax rate guidance is a range of 19.5% to 21.5%, and share count guidance remains unchanged at 69 million to 70 million shares. Ziihera peak sales potential is a range of $3 billion to $5 billion, Modeyso has a $500 million peak expectation in the U.S., and Zepzelca is likely to face a future headwind in 2027.

Jazz Pharmaceuticals Financial Statement Overview

Summary

Strong cash generation is the key positive (TTM operating cash flow ~$1.69B and free cash flow ~$1.57B) alongside very strong gross margins (~85–89%). Offsetting this, profitability has been volatile (net loss in 2025, only modestly positive in TTM) and leverage remains elevated (TTM debt-to-equity ~1.35x), which constrains the balance-sheet profile.

Income Statement

67Positive

Balance Sheet

54Neutral

Cash Flow

81Very Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue4.72B4.27B4.07B3.83B3.66B3.09B
Gross Profit4.16B3.76B3.62B3.40B3.12B2.65B
EBITDA1.17B262.76M1.52B1.45B1.47B1.03B
Net Income205.95M-356.15M560.12M414.83M-224.06M-328.95M
Balance Sheet
Total Assets12.00B11.66B12.01B11.39B10.84B12.30B
Cash, Cash Equivalents and Short-Term Investments2.86B2.44B2.99B1.63B881.48M591.45M
Total Debt5.64B5.42B6.16B5.79B5.81B6.15B
Total Liabilities7.81B7.34B7.92B7.66B7.75B8.33B
Stockholders Equity4.19B4.32B4.09B3.74B3.09B3.97B
Cash Flow
Free Cash Flow1.57B1.15B1.35B1.07B773.78M732.98M
Operating Cash Flow1.69B1.36B1.40B1.09B1.27B778.51M
Investing Cash Flow-977.96M-1.51B-508.19M-163.06M-446.23M-5.21B
Financing Cash Flow-3.86M-873.38M20.52M-305.25M-529.49M3.97B

Jazz Pharmaceuticals Technical Analysis

Technical Analysis SentimentPositive
Last Price240.71

Price Trends

50DMA228.99Positive
100DMA238.93Positive
200DMA220.40Positive

Market Momentum

MACD5.30Negative
RSI58.99Neutral
STOCH68.29Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JAZZ, the sentiment is Positive. The current price of 240.71 is above the 20-day moving average (MA) of 224.78, above the 50-day MA of 228.99, and above the 200-day MA of 220.40, indicating a bullish trend. The MACD of 5.30 indicates Negative momentum. The RSI at 58.99 is Neutral, neither overbought nor oversold. The STOCH value of 68.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JAZZ.

Jazz Pharmaceuticals Risk Analysis

Jazz Pharmaceuticals disclosed 47 risk factors in its most recent earnings report. Jazz Pharmaceuticals reported the most risks in the "Legal & Regulatory" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

3 New Risks
1.We may not realize the anticipated benefits from our acquisition of Chimerix.Q4, 2025
2.Our adoption of AI technologies introduces new risks and uncertainties.Q4, 2025
3.Disruptions at FDA, the SEC and other government agencies and regulatory authorities including due to a reduction in such agencies' workforces, inadequate funding or the current and potential future government shutdowns, could prevent those agencies from performing normal functions on which our business relies, which could negatively impact our business.Q4, 2025

Jazz Pharmaceuticals Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

JAZZ against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
NBIXNBIX80Outperform$16.73B23.7819.74%―37.98%61.95%
HRMYHRMY77Outperform$1.94B10.7318.55%―19.79%-4.89%
PRAXPRAX71Outperform$8.67B-24.00-29.41%―-100.00%0.75%
JAZZJAZZ67Neutral$15.39B67.294.62%―13.48%―
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
AXSMAXSM47Neutral$7.21B-45.12-189.73%―54.16%34.51%
XENEXENE46Neutral$3.86B-8.35-39.80%―-100.00%-21.09%

* Healthcare Sector Average

Performance Comparison

0%50%100%JAZZNBIXXENEAXSMHRMYPRAXDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
JAZZ and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
JAZZJazz Pharmaceuticals240.7164.6336.70%
NBIXNeurocrine Biosciences165.9227.8620.18%
XENEXenon Pharmaceuticals38.78-1.87-4.60%
AXSMAxsome Therapeutics Inc.135.95-10.82-7.37%
HRMYHarmony Biosciences Holdings, Inc.33.01-0.30-0.90%
PRAXPraxis Precision Medicines, Inc.305.06115.7461.13%

Jazz Pharmaceuticals Corporate Events

Business Operations and StrategyExecutive/Board Changes

Jazz Pharmaceuticals Plans Commercial Leadership Transition Ahead

Neutral
Oct 9, 2026

On October 6, 2026, Jazz Pharmaceuticals said Executive Vice President and Chief Commercial Officer Samantha Pearce plans to retire from her role no later than June 30, 2027, or earlier upon the appointment of her successor. The company will initiate...

Business Operations and StrategyPrivate Placements and Financing

Jazz Pharmaceuticals Refinances Term Loan, Extends Maturities

Positive
Sep 23, 2026

On September 23, 2026, Jazz Financing Lux S.à r.l., a wholly owned subsidiary of Jazz Pharmaceuticals, entered into a fourth amendment to its existing credit agreement to extend the maturity and reprice its U.S. dollar term loan B-2 facility original...

Business Operations and StrategyM&A Transactions

Jazz Pharmaceuticals Acquires Actio Biosciences to Expand Epilepsy Portfolio

Positive
Sep 15, 2026

On September 15, 2026, Jazz Pharmaceuticals completed its $820 million upfront acquisition of privately held Actio Biosciences, making Actio an indirect wholly owned subsidiary via a merger structure. As part of the deal, Actio’s non‑ABS‑1230 program...

Business Operations and StrategyStock BuybackPrivate Placements and Financing

Jazz Pharmaceuticals Completes $1.25 Billion Notes Offering

Positive
Aug 31, 2026

On August 31, 2026, Jazz Investments I Limited, a wholly owned subsidiary of Jazz Pharmaceuticals, closed a private offering of $1.25 billion of 1.875% exchangeable senior notes due 2032 to qualified institutional buyers under Rule 144A, following fu...

Business Operations and StrategyProduct-Related Announcements

Jazz wins FDA nod for Ziihera gastric cancer use

Positive
Aug 25, 2026

On August 25, 2026, Jazz Pharmaceuticals said the U.S. Food and Drug Administration approved two Ziihera-containing regimens for first-line treatment of adults with unresectable locally advanced or metastatic HER2-positive gastroesophageal adenocarci...

Business Operations and StrategyM&A Transactions

Jazz Pharmaceuticals to Acquire Actio Biosciences in Merger

Positive
Aug 10, 2026

On August 10, 2026, Jazz Pharmaceuticals, Inc. agreed to acquire Actio Biosciences, Inc. in a cash-based merger valued at an initial $820 million, with customary balance sheet adjustments, making Actio a wholly owned subsidiary. The deal structure co...

Business Operations and StrategyM&A Transactions

Jazz Pharmaceuticals to Acquire Rare Epilepsy Specialist Actio

Positive
Aug 10, 2026

On August 10, 2026, Jazz Pharmaceuticals agreed to acquire privately held Actio Biosciences in a deal featuring an $820 million upfront payment and up to $500 million in milestone-based contingent consideration. The transaction, unanimously approved...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 04, 2026